Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
週三生物技術催化劑綜述-當天結束摘要
- Bristol Myers Squibb (NYSE:BMY) and 2seventy bio (NASDAQ:TSVT) announced positive topline results from KarMMa-3, a Phase 3 study evaluating Abecma (idecabtagene vicleucel) compared to standard combination regimens in adults with multiple myeloma that is relapsed and refractory. Bristol Myers shares traded in a range of $73.95 to $75.32 on a day volume of 8.06 million shares, closed regular trading session at $74.86.
- 百時美施貴寶(紐約證券交易所代碼：BMY)和270人傳記納斯達克公司(TSVT)宣佈了KarMma-3的TOPLINE陽性結果，該研究是一項3期研究，評估ABECMA(依達卡他汀)與標準聯合方案治療復發和難治的成人多發性骨髓瘤的比較。百時美施貴寶股價在73.95美元至75.32美元的區間內交易，當日成交量為806萬股，常規交易時段收於74.86美元。
- Rani Therapeutics (NASDAQ:RANI) announced positive topline results from the single-ascending dose (SAD) portion of its Phase 1 clinical study of its lead asset RT-102 for the potential treatment of osteoporosis. Rani Therapeutics shares traded in a range of $11.03 to $11.51 on a day volume of 13.93 thousand shares, closed regular trading session at $11.10. The company shares are currently trading at $10.75, down 3.2 percent in the after-hours trading session.
- 拉尼治療公司納斯達克(Sequoia Capital：RANI)宣佈，其鉛資產RT-102用於潛在治療骨質疏鬆症的第一階段臨牀研究的單次遞增劑量(SAD)部分獲得陽性背線結果。Rani Treateutics的股票交易價格在11.03美元至11.51美元之間，當日成交量為13.93萬股，常規交易時段收於11.10美元。該公司股票目前的交易價格為10.75美元，在盤後交易中下跌3.2%。
- The U.S. Food and Drug Administration (FDA) has announced 510(k) clearance to ReShape Lifesciences' (NASDAQ:RSLS) Gastro Intestinal Balloon Indicator (GIBI HD) calibration tube for use in gastric and bariatric surgical procedures. ReShape shares traded in a range of $0.44 to $0.8 on a day volume of 11.26 million shares, closed regular trading session at $0.45.
- 美國食品和藥物管理局(FDA)宣佈510(K)計劃獲得批准重塑生命科學納斯達克：RSLS)胃腸道氣囊指示器(GIBI HD)校準管，用於胃和減肥外科手術。重塑股票的交易價格在0.44美元至0.8美元之間，當日成交量為1126萬股，常規交易時段收盤時為0.45美元。
- BridgeBio Pharma (NASDAQ:BBIO) and Sentynl Therapeutics announced that the State of Israel Ministry of Health has approved NULIBRY (fosdenopterin) for Injection as the first therapy in Israel to treat MoCD Type A with the indication to reduce the risk of mortality for patients with molybdenum cofactor deficiency (MoCD) Type A. BridgeBio shares traded in a range of $11.1 to $12.21 on a day volume of 2.04 million shares, closed regular trading session at $11.99.
- 布里奇比奧製藥納斯達克(Sequoia Capital：BBIO)和森特尼治療公司宣佈，以色列衞生部已批准NULIBRY(福登蝶呤)注射，作為以色列第一種治療A型鉬缺乏症的藥物，適應症是降低A型鉬輔因子缺乏症患者的死亡風險。BridgeBio的股票交易量為204萬股，日成交量在11.1美元至12.21美元之間，收盤常規交易時段為11.99美元。
- Lexaria Bioscience (NASDAQ:LEXX) announced that it has received a positive full written response from the Food and Drug Administration (FDA) from its pre-Investigational New Drug meeting regarding DehydraTECH-CBD for the treatment of hypertension. Lexaria shares traded in a range of $2.72 to $2.96 on a day volume of 89.16 thousand shares, closed regular trading session at $2.87.
- Lexaria生物科學納斯達克(Didi Chuxing：Lexx)宣佈在新藥預研會議上收到了美國食品藥品監督管理局(FDA)關於脱氫TECH-CBD治療高血壓的全面積極書面迴應。Lexaria的股價在2.72美元至2.96美元的範圍內交易，日成交量為89.16萬股，常規交易時段收於2.87美元。
- VYNE Therapeutics (NASDAQ:VYNE) announced results from the Phase 2a segment of a Phase 1b/2a clinical trial evaluating FMX114 for the treatment of mild-to-moderate atopic dermatitis (AD). VYNE shares traded in a range of $0.26 to $0.34 on a day volume of 4.75 million shares, closed regular trading session at $0.31.
- Vyne治療公司納斯達克公司(Temasek Holdings：Vyne)宣佈了評估FMX114治療輕中度特應性皮炎(AD)的1b/2a階段臨牀試驗的2a階段結果。Vyne的股價在0.26美元至0.34美元的範圍內交易，當日成交量為475萬股，常規交易時段收於0.31美元。
- LianBio (NASDAQ:LIAN) announced the completion of enrollment in the Phase 3 EXPLORER-CN clinical study of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), expect to report topline results in mid-2023. LianBio shares traded in a range of $2.41 to $2.86 on a day volume of 572.39 thousand shares, closed regular trading session at $2.7.
- 聯眾生物納斯達克(Sequoia Capital：LIAN)宣佈，馬伐他汀在中國症狀性梗阻性肥厚型心肌病(OHCM)患者中的3期EXPLOR-CN臨牀研究已經完成，預計將於2023年年中報告TOPLINE結果。LianBio的股價在2.41美元至2.86美元的範圍內交易，當日成交量為572.39萬股，常規交易時段收於2.7美元。
- TRACON Pharmaceuticals (NASDAQ:TCON) announced that the Independent Data Monitoring Committee for the ENVASARC pivotal trial has recommended that the trial proceed as planned following the review of three week safety data from more than 20 patients enrolled into the trial. TRACON shares traded in a range of $1.83 to $2.15 on a day volume of 167.43 thousand shares, closed regular trading session at $2.07. The company shares are currently trading at $2.15, up 3.86 percent in the after-hours trading session.
- TRACON製藥公司納斯達克公司(Temasek Holdings：TCON)宣佈，ENVASARC關鍵試驗的獨立數據監測委員會在審查了20多名登記參加試驗的患者的三週安全數據後，建議試驗按計劃進行。TRACON股價在1.83美元至2.15美元的區間內交易，當日成交量為167.43萬股，常規交易時段收盤報2.07美元。該公司股票目前的交易價格為2.15美元，在盤後交易中上漲了3.86%。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。